Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multicenter Phase II study of patients with advanced
HR+/HER2- breast cancer who are untreated or have failed previous first-line endocrine
therapyćThe primary objective of this study was to explore the efficacy and safety of the
PD-L1 inhibitor adebrelimab in combination with the CDK4/6 inhibitor Dalpiciclib and standard
endocrine therapy in advanced HR+/ HER2-breast cancer.